Mylan recalls injectable cancer meds, most produced for Pfizer

Top of mind for Mylan ($MYL) may be fending off an unsolicited $40 billion buyout offer from competitor Teva ($TEVA), but it still has to take care of business as usual. Right now that includes recalling 8 lots of injectable cancer drugs, most of them manufactured for Pfizer ($PFE), after particulate was discovered in vials. More from FiercePharmaManufacturing

Suggested Articles

Turns out Procter & Gamble didn’t want Pfizer’s consumer health unit after all. But it did want Merck KGaA’s.

Private equity firm, in exclusive talks with Sanofi, says it'll invest to pump up Zentiva into an "independent European generics leader."

With suitor Takeda circling Shire, the Dublin-based target has pulled off a deal of its own.